High Dose Ascorbic Acid for Plasma Cell Disorders
Summary
Third Opinion Trial Synopsis:
This is a study that will test a new treatment for people with a type of cancer called multiple myeloma. The treatment uses a low dose of a drug called melphalan and a high dose of vitamin C. The study will focus on whether the treatment is safe and whether it works better than other treatments that did not work before.
This is a study that will test a new treatment for people with a type of cancer called multiple myeloma. The treatment uses a low dose of a drug called melphalan and a high dose of vitamin C. The study will focus on whether the treatment is safe and whether it works better than other treatments that did not work before.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: